SCHEMBL28849500

SCHEMBL28849500

C=Cc1cc(C(=O)OF)ccc1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 2/20 0.33
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA7 P43166 2/20 0.33
CA9 Q16790 2/20 0.33
CA14 Q9ULX7 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
SLC22A8 Q8TCC7 1/20 0.33
XDH P47989 1/20 0.33
CYP2C9 P11712 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16084978 0.85 ALDH1A1 (0.49) NOTUMALDH1A1HPGDKMT2AMAPT
SCHEMBL26093025 0.82 CA12 (0.54) ALDH1A1HPGDKMT2AMAPTCA12
SCHEMBL8528733 0.79 TSHR (0.47) ALDH1A1HPGDKMT2AMAPTCA12
SCHEMBL15500764 0.77 KMT2A (0.49) ALDH1A1KMT2AMAPTCA1CA2
SCHEMBL879847 0.71 ALDH1A1 (0.49) NOTUMALDH1A1HPGDKMT2AMAPT
SCHEMBL27958440 0.70 MAPT (0.44) ALDH1A1HPGDKMT2AMAPTTDP1
SCHEMBL12958097 0.70 MEN1 (0.37) KMT2ASMN1; SMN2
SCHEMBL28841147 0.70 HPGD (0.37) ALDH1A1HPGDKMT2AMAPTTDP1
SCHEMBL4129229 0.70 ERN1 (0.50) NOTUMALDH1A1HPGDKMT2AMAPT
SCHEMBL3154375 0.70 CA12 (0.51) ALDH1A1HPGDKMT2AMAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107205972-A Substituted N- (2- (amino) -2-oxoethyl) benzamide inhibitors of autotaxin and their preparation and use in the treatment of LPA-dependent or LPA-mediated diseases X-RX股份有限公司 2017-09-26 CN disclosed